PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-aden...

Descripción completa

Detalles Bibliográficos
Autores principales: Franzese, Elisena, Diana, Anna, Centonze, Sara, Pignata, Sandro, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303974/
https://www.ncbi.nlm.nih.gov/pubmed/32596142
http://dx.doi.org/10.3389/fonc.2020.00782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303974/
https://www.ncbi.nlm.nih.gov/pubmed/32596142
http://dx.doi.org/10.3389/fonc.2020.00782

Ejemplares similares